- Global Pharma News & Resources

Enterome to Present at Jefferies Virtual Next Generation IBD Therapeutics Summit

PARIS and CAMBRIDGE, MA, Sept. 22, 2020 /PRNewswire/ -- ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today announces that Pierre Belichard, Chief Executive Officer, and Christophe Bonny, Chief Scientific Officer, will present at the Jefferies Virtual Next Generation IBD Therapeutics Summit, which will take place September 23-24, 2020.

The presentation, in the form of a live fireside chat, will take place on Wednesday, September 23, at 11:30-12:10 Eastern Daylight Time.


Pierre Belichard, CEO

Media Relations

Mark Swallow / Sylvie Berrebi / David Dible
Citigate Dewe Rogerson
Tel. +44 207 638 9571 /

Investor Relations

Melody Carey
Rx Communications Group
Tel. +1 917 322 2571 /

About Enterome

Enterome is a world leader in the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system (the 'microbiome-immunoinflammation axis'). Enterome is leveraging this expertise to develop a pipeline of clinical and pre-clinical candidates (small molecules, proteins and peptides) with a focus on cancer, autoimmune, inflammatory and metabolic diseases.

Enterome has two unique platforms that are generating highly promising drug candidates:

  • OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463, is being prepared as a clinical candidate for B-cell malignancies (lymphomas and leukemias).
  • EndoMimics: a new generation of biologics for inflammatory diseases (EM101), Type 2 diabetes and inflammatory bowel disease.

These highly productive platforms have been created using Enterome's world-leading Metasecretome technology, which gives it an unrivalled ability to generate precision drugs by using the natural reservoir of thousands of safe and tolerized effector proteins that are produced by the gut bacteria.

In addition, Enterome's clinical candidate EB8018 (also referred to as sibofimloc/TAK-018), which selectively blocks the virulence factor FimH, is advancing through clinical trials in Crohn's disease. EB8018 has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US.

Enterome is headquartered in Paris (France) with operations in Boston (US) and is backed by leading venture capital investors.

For more information please visit the company's website at: 

View original content:

SOURCE Enterome

Editor Details

Last Updated: 22-Sep-2020